Court of Appeal Reinstates Suit Against Drug Manufacturer

May 8, 2020

The Court of Appeal has reinstated a suit brought by boys who developed abnormal breast tissue growth (gynecomastia) after taking Risperdal. The Court of Appeal rejected the manufacturer’s argument that federal law made it impossible to give adequate warnings about the risk of gynecomastia. Martin represented the plaintiffs on appeal.